Converting Equol Nonproducers to Producers: A Systematic Review of Randomized Clinical Trials
Open Access
- 27 September 2026
- journal article
- review article
- Published by Wiley in Food Science & Nutrition
- Vol. 14 (10) , e72394
Abstract
Soy isoflavones have been associated with benefits for menopausal symptoms, cardiovascular health, and cognitive function, yet randomized clinical trials (RCTs) in Western countries have produced inconsistent results. A key factor may be equol, a metabolite of daidzein with stronger estrogenic and antioxidant effects, produced at lower rates in Western than in East Asian populations. This systematic review evaluates RCTs aimed at converting equol nonproducers to producers (CRD420251038428). We searched PubMed, Embase, and Web of Science for RCTs published between 1991 and 2025. Twelve RCTs ( n = 730, 85.5% female) met inclusion criteria. Interventions included soy isoflavones alone, soy with probiotics, fermented soy products, seaweed, and wheat bran. Studies were conducted in Japan ( n = 1), Brazil ( n = 1), and Western countries ( n = 10), with durations ranging from a single dose to 2.5 years. Study quality was assessed using the National Heart, Lung, and Blood Institute evaluation tool. None of the interventions significantly converted equol nonproducers into producers, with methodological limitations including small sample sizes, inconsistent equol measurement, and heterogeneous populations compromising reliability. Achieving equol producer status could unlock the full nutritional potential of soy isoflavones for menopausal, cardiovascular, and cognitive health. Future studies should prioritize standardized equol measurement, microbiome‐targeted interventions, and well‐powered, diverse populations to develop effective dietary strategies for Western populations where soy intake and equol production remain low.Keywords
Funding Information
- National Institute on Aging (R01AG074971)
- National Institutes of Health (R01HL169332)
This publication has 55 references indexed in Scilit:
- ACE trial design: Equol targeting estrogen receptor‐β in vascular and cognitive agingAlzheimer's & Dementia: Translational Research & Clinical Interventions, 2025
- Impact of prebiotics on equol production from soymilk isoflavones by two Bifidobacterium speciesHeliyon, 2020
- Influence of gender and menopausal status on gut microbiotaMaturitas, 2018
- Effect of soy nuts and equol status on blood pressure, lipids and inflammation in postmenopausal women stratified by metabolic syndrome statusMetabolism, 2015
- Nutrition in the Prevention and Treatment of Cognitive Decline2014
- Soy isoflavones and their relationship with microflora: beneficial effects on human health in equol producersPhytochemistry Reviews, 2013
- Bioconversion of daidzein to equol by Bifidobacterium breve 15700 and Bifidobacterium longum BB536Journal of Functional Foods, 2012
- Equol production changes over time in postmenopausal womenThe Journal of Nutritional Biochemistry, 2012
- Increased probiotic yogurt or resistant starch intake does not affect isoflavone bioavailability in subjects consuming a high soy dietNutrition, 2007
- Transformation of isoflavone phytoestrogens during the fermentation of soymilk with lactic acid bacteria and bifidobacteriaFood Microbiology, 2006